Treatment of irritable bowel syndrome

Article (Published Version)


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/36105/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
Treatment of irritable bowel syndrome

Strategies involve single receptor blockade and non-pharmacological interventions

Irritable bowel syndrome is characterised by diverse symptoms including abdominal pain, altered bowel function (increased bowel frequency, constipation), bloating, abdominal distension, the sensation of incomplete evacuation, and the increased passage of mucus. The current favoured model to explain the symptoms includes central and end organ components. These may be combined into an integrated hypothesis that incorporates psychological factors (stress, distress, affective disorder) and dysfunction of the gut (disorders of motility, visceral hypersensitivity). Current standard drug treatment generally entails a symptom directed approach with drugs aimed at pain, constipation, and diarrhoea. Development of new drugs has focused mainly on agents that modify the effects of 5-hydroxytryptamine (5-HT) in the gut. Alternatives to this single receptor approach exist, although not all patients respond to educational and psychological interventions, and treatment with drugs will remain an option for non-responders.

As a mediator of the motor and secretory responses to the ingestion of food, 5-HT has an important physiological role. Growing evidence shows that some aspects of the pathophysiology of irritable bowel syndrome may affect the 5-HT axis. Specific 5-HT1 and 5-HT3 receptors have been identified as therapeutic targets. Alosetron and cilansetron, which are 5-HT3 receptor antagonists, were devised to reduce pain and retard transit and therefore be beneficial in irritable bowel syndrome that manifests predominantly as diarrhoea. Randomised controlled trials indicate that both have some efficacy in patients with diarrhoea predominant irritable bowel syndrome, although alosetron is effective only in women. Although alosetron was licensed in the United States in 2000, it was subsequently withdrawn because many patients developed ischaemic colitis and severe constipation. Many of these patients required admission to hospital, and three of them died. Ischaemic colitis has also been reported with cilansetron and seems likely to be a class specific adverse effect. Recent evidence shows that ischaemic colitis may be increased in patients with irritable bowel syndrome, and that this may be influencing the effect of alosetron adversely. The Food and Drug Administration, however, has challenged this position.

The second problem relates to whether the statistically significant therapeutic gain of about 12% over placebo translates into a clinically important benefit for patients with irritable bowel syndrome. A group of experts has advised that a 10-15% therapeutic gain would be appropriate for a new drug for irritable bowel syndrome, although this statement seems to lack evidence. Tegaserod, a 5-HT3 receptor partial agonist and a prokinetic in the gut, is effective in women with constipation predominant irritable bowel syndrome. The therapeutic gain over placebo varied substantially in different trials at 5-20%, again raising the question whether this is a clinically important effect and whether a similar therapeutic gain might be obtained with a simple laxative or soluble fibre. A Cochrane review confirms the drug's efficacy in improving the overall symptoms in irritable bowel syndrome, with a number needed to treat between 14 and 20, but finds no effect on individual symptoms of pain and discomfort. Tegaserod is now available in the United States and some other countries for the treatment of constipation predominant irritable bowel syndrome in women. It is still under evaluation by the European Agency for Evaluation of Medicinal Products. Tegaserod has also been linked to ischaemic colitis, but this assertion has been rebutted on the basis that this merely represents the incidence in the general population.

The science linking 5-HT and irritable bowel syndrome is appealing, and some progress has been made in translating this knowledge into new treatments, however, we still have no pharmacological intervention that will resolve all aspects of the symptom complex of irritable bowel syndrome. The importance of psychosocial factors in the development of irritable bowel syndrome has been recognised for decades. Psychological interventions (psychotherapy, short and long term hypnotherapy, cognitive behaviour therapy) and antidepressants (low and conventional doses) are effective. Cognitive behaviour therapy has an impressive therapeutic gain of 33% over control. Multidisciplinary education and comprehen-
sive self management programmes in women have also been shown to work.15

Thompson, however, said recently that most patients with irritable bowel syndrome require no drug treatment.24 For most patients, irritable bowel syndrome is an intrusive and sometimes debilitating condition, but it is never fatal in itself. Therefore, we must be certain that any new treatment is truly effective and has a clinically significant benefit over placebo, and must do no harm.

Michael J G Farthing  professor of medicine
St George’s Hospital Medical School, London SW17 0RE (m.farthing@sghms.ac.uk)

Competing interests: MF has acted as an adviser to Novartis Pharmaceuticals, GlaxoSmithKline, Pfizer, and Solvay Pharmaceuticals with respect to the development and evaluation of new drugs for the treatment of irritable bowel syndrome.

9 Jølleson BK, Sheftelina MA, Cummings S, Tegaserod and ischaemic coli-
12 Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Dun-
14 The British model of general practice is rightly admired.1-2 Explicit responsibility for a defined population facilitates a public health dimension to health care. The training emphasises teamwork, consultation skills, management of undifferentiated symptoms, and the integration of psychosocial and biological aspects of health and illness in the context of the family and community. These skills are crucial for working with children and young people and the recently published national service framework for children has a whole section on primary care.3-8 Therefore, to question the future of children’s health care in general practice may seem perverse, but there are several causes for concern.

Although serious acute childhood illness has become less common, both professionals and parents worry about overlooking potentially life threatening conditions. When a child is ill outside surgery hours, parents accept that they are unlikely to see their usual doctor and the new contract permits general practitioners to opt out of 24 hour responsibilities.9-15 Out of hours services, such as NHS Direct, often direct parents to a primary care assessment facility or a hospital emergency department. Even if primary care organisations can sustain 24 hour cover, more parents may well decide to bypass primary care and seek emergency care in hospitals, accelerating the move towards centralised emergency services and more short stay admissions.9-15 Rare complex paediatric conditions need specialised management, but chronic neurological, psychosocial, and mental health problems (in particular conduct and behavioural disorders) make up a large part of modern paediatrics,1 yet their care remains fragmented and the resources allocated inadequate.5

Primary care for children in the 21st century

General practitioners must adapt to the changed spectrum of illnesses

The 1990 contract encouraged general practitioners to provide child health surveillance programmes. They are well placed to understand how individual social circumstances might influence each child’s health and development.24 The growing evidence for child health screening and promotion in preschool facilities and schools underlies government support for a child health promotion programme.3-7 16

Although some doctors enjoy preventive care and caring for well children, many believe that this is best delivered by other professional staff such as health visitors. The latter, however, work increasingly on a geographical basis separate from general practices. Physical examination, once the preserve of doctors, can be undertaken by appropriately trained nurses and midwives, at least where the newborn is concerned and non-medical staff are increasingly functioning as independent practitioners.25 Health promotion for teenagers is also problematic; they often prefer clinics near their school or college for sensitive issues like sexual health because of concerns about the privacy and confidentiality offered by their local general practice, despite many practices having sought to reassure young people by establishing special teenage clinics.7 16

In other European Union countries and the United States,3 17 office based paediatricians provide most care,